budesonide easyhaler 100 µg pulver zur inhalation
orion corporation - budesonid - pulver zur inhalation - 100 µg - budesonid 100 µg/dose - budesonide
budesonide easyhaler 400 µg pulver zur inhalation
orion corporation - budesonid - pulver zur inhalation - 400 µg - budesonid 400 µg/dose - budesonide
budesonide easyhaler 200 µg pulver zur inhalation
orion corporation - budesonid - pulver zur inhalation - 200 µg - budesonid 200 µg/dose - budesonide
budesonide ferring 9 mg retardtablette
ferring - budesonid - retardtablette - 9 mg - budesonid 9 mg - budesonide
novolizer budesonide 200 µg pulver zur inhalation
mylan epd - budesonid - pulver zur inhalation - 200 µg - budesonid 200 µg/dose - budesonide
novolizer budesonide 400 µg pulver zur inhalation
mylan epd - budesonid - pulver zur inhalation - 400 µg - budesonid 400 µg/dose - budesonide
budesonide liconsa 3 mg hard caps. modif.-rel.
budesonide liconsa 3 mg gél. lib. modif.
budesonide liconsa 3 mg harde caps. geregul. afgifte
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medikamente für obstruktive atemwegserkrankungen, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).